Advertisement

Supportive Care in Cancer

, Volume 22, Issue 8, pp 2261–2269 | Cite as

Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review

  • Floortje MolsEmail author
  • Tonneke Beijers
  • Gerard Vreugdenhil
  • Lonneke van de Poll-Franse
Review Article

Abstract

Background

The objective of this study was to systematically review all available literature concerning chemotherapy-induced peripheral neuropathy (CIPN) and quality of life (QOL) among cancer patients.

Methods

A computerized search of the literature was performed in December 2013. Articles were included if they investigated CIPN and QOL among cancer patients. Twenty-five articles were selected and were subjected to a 13-item quality checklist independently by two investigators.

Results

The methodological quality of the majority of the selected studies was adequate to high. The included studies differed tremendously with respect to study design (19 prospective studies, 5 cross-sectional, 1 both cross-sectional and prospective), patient population (lung, colorectal, ovarian, endometrial, cervical or breast cancer, lymphoma, acute lymphoblastic leukemia, or a mixed population), number of included patients (ranging from 14 to 1643), and ways to assess CIPN (objectively, subjectively, or both). Of the 25 included studies, 11 assessed the association of CIPN on patients’ QOL. While three of these studies did not find an association between CIPN and QOL, the others concluded that more CIPN was associated with a lower QOL.

Implications for cancer survivors

Although the included studies in this systematic review were very diverse, which impedes drawing firm conclusions on this topic, CIPN is likely to have a negative association with QOL. The variety of the studied patient populations and chemotherapeutic agents in the existing studies calls for further studies on this topic. These studies are preferably prospective in nature, include a large number of patients, and assess QOL and CIPN with validated questionnaires.

Keywords

Chemotherapy-induced peripheral neuropathy Cancer Quality of life 

Notes

Funding

The present research was supported by a VENI grant (#451-10-041) from the Netherlands Organisation for Scientific Research (The Hague, The Netherlands) awarded to Floortje Mols and a Cancer Research Award from the Dutch Cancer Society (#UVT-2009-4349) to Lonneke V. van de Poll-Franse.

Conflict of interest

There is no conflict of interest.

References

  1. 1.
    Gutiérrez-Gutiérrez G et al (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12(2):81–91PubMedCrossRefGoogle Scholar
  2. 2.
    Kannarkat G, Lasher E, Schiff D (2007) Neurologic complications of chemotherapy agents. Curr Opin Neurol 20(6):719–725PubMedGoogle Scholar
  3. 3.
    Sukel MP et al (2008) Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990–2006 in the southeastern Netherlands. Eur J Cancer 44(13):1846–1854PubMedCrossRefGoogle Scholar
  4. 4.
    Dassen AE et al (2010) Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 46(6):1101–1110PubMedCrossRefGoogle Scholar
  5. 5.
    Elferink MA et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989–2006. Eur J Cancer 46(8):1421–1429PubMedCrossRefGoogle Scholar
  6. 6.
    van Steenbergen LN et al (2012) Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Ann Oncol 23(11):2805–2811PubMedCrossRefGoogle Scholar
  7. 7.
    Beijers AJ, Jongen JL, Vreugdenhil G (2012) Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 70(1):18–25PubMedGoogle Scholar
  8. 8.
    Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. doi: 10.1007/s00520-014-2242-z Google Scholar
  9. 9.
    Markman M (1996) Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol 122(9):511–512PubMedCrossRefGoogle Scholar
  10. 10.
    Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389–1391PubMedCrossRefGoogle Scholar
  11. 11.
    Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331PubMedCrossRefGoogle Scholar
  12. 12.
    Bezjak A et al (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22(22):4595–4603PubMedCrossRefGoogle Scholar
  13. 13.
    Brundage M et al (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. Ann Oncol Off J Eur Soc Med Oncol / ESMO 23(8):2020–2027CrossRefGoogle Scholar
  14. 14.
    Bruner DW et al (2007) Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. Qual Life Res Int J Qual Life Asp Treat Care and Rehab 16(1):89–100CrossRefGoogle Scholar
  15. 15.
    Butler L et al (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol Off J Am Soc Clin Oncol 22(12):2461–2468CrossRefGoogle Scholar
  16. 16.
    Calhoun EA et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748PubMedCrossRefGoogle Scholar
  17. 17.
    Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Cella D et al (2003) Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 98(4):822–831PubMedCrossRefGoogle Scholar
  19. 19.
    Cella D et al (2010) Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 119(3):531–537PubMedCrossRefGoogle Scholar
  20. 20.
    Driessen CM et al (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Griffith KA et al (2014) Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer 22(5):1161–1169PubMedCrossRefGoogle Scholar
  22. 22.
    Hershman DL et al (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774PubMedCrossRefGoogle Scholar
  23. 23.
    Hilpert F et al (2005) Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 13(10):797–805Google Scholar
  24. 24.
    Kautio AL et al (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag 35(1):31–39CrossRefGoogle Scholar
  25. 25.
    Kim BJ et al (2010) Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 19(8):1097–1103PubMedCrossRefGoogle Scholar
  26. 26.
    Lee SM et al (2009) Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(31):5248–5254CrossRefGoogle Scholar
  27. 27.
    Mols F et al (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. doi: 10.1200/JCO.2013.49.1514 PubMedGoogle Scholar
  28. 28.
    Morita S et al (2003) Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 33(9):470–476PubMedCrossRefGoogle Scholar
  29. 29.
    Ostchega Y, Donohue M, Fox N (1988) High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11(1):23–32PubMedCrossRefGoogle Scholar
  30. 30.
    Ramchandren S et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst: JPNS 14(3):184–189PubMedCrossRefGoogle Scholar
  31. 31.
    Richter R et al (2012) Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase II study of the North Eastern German Society of Gynecological Oncology. Anticancer Res 32(9):3969–3976PubMedGoogle Scholar
  32. 32.
    Shimozuma K et al (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(12):3355–3364Google Scholar
  33. 33.
    Smith EM et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA J Am Med Assoc 309(13):1359–1367CrossRefGoogle Scholar
  34. 34.
    Sorbe B et al (2012) A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40(3):773–781PubMedGoogle Scholar
  35. 35.
    Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28PubMedCrossRefGoogle Scholar
  36. 36.
    Wenzel LB et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 25(4):437–443CrossRefGoogle Scholar
  37. 37.
    Mols F et al (2005) Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer 41(17):2613–2619PubMedCrossRefGoogle Scholar
  38. 38.
    Den Oudsten BL, Van Heck GL, De Vries J (2007) Quality of life and related concepts in Parkinson’s disease: a systematic review. Mov Disord 22(11):1528–1537CrossRefGoogle Scholar
  39. 39.
    Pachman DR et al (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377–387PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Floortje Mols
    • 1
    • 2
    Email author
  • Tonneke Beijers
    • 3
  • Gerard Vreugdenhil
    • 3
    • 4
  • Lonneke van de Poll-Franse
    • 1
    • 2
  1. 1.CoRPS - Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical PsychologyTilburg UniversityTilburgThe Netherlands
  2. 2.Comprehensive Cancer Centre Netherlands (CCCN)Eindhoven Cancer RegistryEindhovenThe Netherlands
  3. 3.Department of Internal MedicineMaxima Medical CentreVeldhovenThe Netherlands
  4. 4.Department of Medical OncologyMaastricht University Medical CentreMaastrichtThe Netherlands

Personalised recommendations